Healthcare Services

A Significant Growth Driver for the Human Immunodeficiency Virus Therapeutics Market Is the Increase In Unprotected Sexual Practices Fueling The Market Due To Limited Access To Contraception And Lack Of Comprehensive Sex Education

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Human Immunodeficiency Virus Therapeutics Market In 2026 And What Value Is Projected For 2030?

The human immunodeficiency virus therapeutics market has experienced significant expansion in recent years. It is projected to increase from $14.9 billion in 2025 to $15.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.6%. The historical growth in this market can be attributed to the global prevalence of HIV infections, the widespread adoption of antiretroviral therapy, government-funded HIV treatment initiatives, the increasing availability of generic HIV drugs, and enhanced survival rates among HIV patients.

The human immunodeficiency virus therapeutics market is projected to experience robust expansion in the coming years. Its valuation is anticipated to reach $19.4 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.4%. This anticipated growth throughout the forecast period stems from several factors, including an escalating demand for long-acting HIV treatments, a heightened emphasis on individualized HIV therapy plans, broader access to HIV care in lower and middle-income nations, increasing financial commitments towards advanced antiretroviral medications, and a greater focus on managing HIV as a chronic condition throughout a patient’s life. Key trends shaping the forecast period encompass the wider embrace of combination antiretroviral therapies, a noticeable move towards long-acting injectable HIV treatments, an intensified effort on achieving early and lasting viral suppression, an increase in the availability of generic antiretroviral drugs, and a heightened focus on ensuring treatment compliance and simpler dosing schedules.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23419&type=smp

What Drivers Are Influencing The Human Immunodeficiency Virus Therapeutics Market?

The increasing occurrence of unprotected sexual practices is anticipated to fuel the expansion of the human immunodeficiency virus therapeutics market in the future. Unprotected sexual practices involve sexual activities without barrier protection, which elevates the danger of sexually transmitted infections (STIs) and unplanned pregnancies. A deficiency in thorough sex education results in inadequate knowledge of safe practices, encouraging risky behavior among young individuals. Human immunodeficiency virus therapeutics play a role in lowering the danger of HIV transmission resulting from unprotected sexual practices by reducing viral load to imperceptible levels, thus stopping further spread of the infection. For example, in November 2024, the Centers for Disease Control and Prevention, a US-based government agency, reported from a 2023 survey of U.S. high school students that 32% had engaged in sexual intercourse at least once, and 48% did not use a condom during their most recent sexual encounter. Consequently, the rising frequency of unprotected sexual practices is propelling the growth of the human immunodeficiency virus therapeutics market.

What Are The Key Segments Of The Human Immunodeficiency Virus Therapeutics Market?

The human immunodeficiency virus therapeutics market covered in this report is segmented –

1) By Drug Type: Branded Drugs, Generic Drugs

2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

3) By End-user: Hospitals And Clinics, Specialty Centers

Subsegments:

1) By Branded Drugs: Biktarvy, Triumeq, Genvoya, Juluca, Dovato, Isentress, Prezista

2) By Generic Drugs: Tenofovir Disoproxil Fumarate (TDF), Lamivudine, Efavirenz, Zidovudine, Nevirapine, Abacavir, Ritonavir

What Industry Trends Are Redefining The Human Immunodeficiency Virus Therapeutics Market?

Leading companies within the Human Immunodeficiency Virus Therapeutics market are concentrating on developing long-lasting, highly effective prevention and treatment solutions, improving availability through supportive reimbursement initiatives, and advancing innovative clinical strategies to boost patient adherence and lower the rate of new HIV infections. For example, in June 2025, Gilead Sciences, a US-based healthcare firm, obtained FDA approval for Yeztugo (lenacapavir), which stands as the first and only twice-yearly injectable PrEP option, representing a significant advancement in HIV prevention. Supported by Phase 3 PURPOSE 1 and PURPOSE 2 trial data, the drug exhibited exceptional efficacy, with ≥99.9% of participants remaining HIV-negative. This long-acting injection aims to mitigate barriers such as adherence difficulties, stigma, and limited awareness that currently restrict PrEP utilization. The approval of Yeztugo offers a promising new tool to aid in reducing new HIV infections across diverse populations. Additionally, Gilead is implementing extensive access measures, including partnerships with insurance providers, co-pay assistance for eligible patients, and free access for uninsured individuals through specific assistance programs.

Who Are The Leading Companies Operating In The Human Immunodeficiency Virus Therapeutics Market?

Major companies operating in the human immunodeficiency virus therapeutics market are Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., AbbVie Inc., Johnson & Johnson, Bristol Myers Squibb Company, Pfizer Inc., F Hoffmann La Roche Ltd., Sanofi SA, Novartis International AG, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Cipla Limited, Aurobindo Pharma Limited, Hetero Labs Limited, Viatris Inc., Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr Reddy’s Laboratories Ltd., Mylan N.V.

Read the full human immunodeficiency virus therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/human-immunodeficiency-virus-therapeutics-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Human Immunodeficiency Virus Therapeutics Market?

North America was the largest region in the human immunodeficiency virus therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency virus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Human Immunodeficiency Virus Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23419&type=smp

Browse Through More Reports Similar to the Global Human Immunodeficiency Virus Therapeutics Market 2026, By The Business Research Company

Antiviral Combination Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Infectious Disease Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/infectious-disease-therapeutics-global-market-report

Human Immunodeficiency Virus Hiv Diagnosis Global Market Report

https://www.thebusinessresearchcompany.com/report/human-immunodeficiency-virus-hiv-diagnosis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795